{"id":30352,"date":"2024-11-19T13:44:58","date_gmt":"2024-11-19T08:14:58","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=30352"},"modified":"2024-11-19T13:45:00","modified_gmt":"2024-11-19T08:15:00","slug":"pharma-news-for-regeneron-astrazeneca-syndax","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-astrazeneca-syndax","title":{"rendered":"FDA Approves PTC&#8217;s AADC Gene Therapy; DUPIXENT sBLA Acceptance for Urticaria; CHMP Recommends TAGRISSO for EGFR Lung Cancer; FDA Approves DANZITEN for CML; Syndax Wins FDA Approval for REVUFORJ in Acute Leukemia"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a043b5611dcf\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a043b5611dcf\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-astrazeneca-syndax\/#FDA_Approves_AADC_Deficiency_Gene_Therapy_by_PTC_Therapeutics\" >FDA Approves AADC Deficiency Gene Therapy by PTC Therapeutics<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-astrazeneca-syndax\/#Sanofi_and_Regenerons_DUPIXENT_sBLA_Accepted_by_FDA_for_Chronic_Spontaneous_Urticaria\" >Sanofi and Regeneron\u2019s DUPIXENT sBLA Accepted by FDA for Chronic Spontaneous Urticaria<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-astrazeneca-syndax\/#CHMP_Recommends_TAGRISSO_for_Unresectable_EGFR-Mutated_Lung_Cancer\" >CHMP Recommends TAGRISSO for Unresectable EGFR-Mutated Lung Cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-astrazeneca-syndax\/#FDA_Approves_DANZITEN_for_Chronic_Myeloid_Leukemia\" >FDA Approves DANZITEN for Chronic Myeloid Leukemia<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-astrazeneca-syndax\/#Syndax_Gains_FDA_Approval_for_REVUFORJ_in_Acute_Leukemia\" >Syndax Gains FDA Approval for REVUFORJ in Acute Leukemia<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-approves-aadc-deficiency-gene-therapy-by-ptc-therapeutics\"><span class=\"ez-toc-section\" id=\"FDA_Approves_AADC_Deficiency_Gene_Therapy_by_PTC_Therapeutics\"><\/span>FDA Approves AADC Deficiency Gene Therapy by PTC Therapeutics<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>PTC Therapeutics, Inc. has secured FDA accelerated approval for <strong>KEBILIDI (eladocagene exuparvovec-tneq)<\/strong>, marking a historic milestone as the first-ever gene therapy directly administered to the brain in the United States. This innovative therapy addresses <strong>aromatic L-amino acid decarboxylase (AADC) deficiency<\/strong>, a rare and life-threatening genetic disorder.&nbsp;<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>&#8220;PTC has once again pioneered a new approach to treating highly morbid neurologic diseases,&#8221; said<\/em><strong><em> Dr. Matthew B. Klein,<\/em><\/strong><em> <\/em><strong><em>CEO of PTC Therapeutics. <\/em><\/strong><em>He emphasized the company\u2019s commitment to delivering transformative treatments to patients with this devastating condition.<\/em><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>The therapy&#8217;s approval stems from its ability to restore dopamine synthesis in the brain, enabling children and adults with AADC deficiency to achieve critical motor development milestones. <\/em><strong><em>&#8220;We look forward to bringing this transformational gene therapy to patients in the United States,&#8221; <\/em><\/strong><em>added <\/em><strong><em>Klein<\/em><\/strong><em>, highlighting their preparation efforts, including establishing centers of excellence and training surgeons in the delivery procedure.<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>KEBILIDI\u2122, a one-time gene replacement therapy, is administered directly to the putamen of the brain through stereotactic neurosurgery. Clinical trials have demonstrated significant improvements in motor function and overall quality of life for patients. This FDA nod was based on data from an ongoing global study, with confirmatory evidence to be gathered from long-term patient follow-ups.<\/p>\n\n\n\n<p>AADC deficiency, often fatal and profoundly disabling, leaves children unable to synthesize dopamine, causing severe motor dysfunction, oculogyric crises, and life-threatening complications. With its approval, KEBILIDI offers hope to families affected by this condition, positioning PTC Therapeutics at the forefront of neurologic innovation.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-sanofi-and-regeneron-s-dupixent-sbla-accepted-by-fda-for-chronic-spontaneous-urticaria\"><span class=\"ez-toc-section\" id=\"Sanofi_and_Regenerons_DUPIXENT_sBLA_Accepted_by_FDA_for_Chronic_Spontaneous_Urticaria\"><\/span>Sanofi and Regeneron\u2019s DUPIXENT sBLA Accepted by FDA for Chronic Spontaneous Urticaria<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <strong>FDA has accepted the resubmission of DUPIXENT&#8217;s (dupilumab) sBLA<\/strong> for <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-spontaneous-urticaria-market\" class=\"ek-link\">treating chronic spontaneous urticaria (CSU)<\/a> in patients aged 12 and older whose condition is inadequately managed with antihistamines. If approved, DUPIXENT would become the first targeted therapy for CSU in over a decade, with a decision expected by <strong>April 18, 2025<\/strong>. The resubmission is backed by pivotal data from the <strong>LIBERTY-CUPID Phase 3 trials<\/strong>, showing significant reductions in itch and hive activity among patients on standard antihistamine treatments.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Dr. George Yancopoulos, President and Chief Scientific Officer at Regeneron, highlighted the significance of the submission, stating, &#8220;Patients with inadequately controlled CSU often suffer debilitating symptoms. These pivotal results reinforce DUPIXENT&#8217;s potential as a transformative option for this population.&#8221; Similarly, Dr. John Reed, Global Head of R&amp;D at Sanofi, noted, &#8220;This milestone underscores our commitment to expanding DUPIXENT\u2019s impact across allergic and inflammatory diseases.&#8221;<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The LIBERTY-CUPID clinical program demonstrated DUPIXENT\u2019s efficacy across multiple studies, with <strong>Study C confirming significant reductions in itch and hive activity<\/strong>, consistent with earlier results from Study A. Safety data were generally in line with DUPIXENT\u2019s established profile, with common side effects including injection site reactions and mild COVID-19 infections.<\/p>\n\n\n\n<p>Currently approved for multiple indications, DUPIXENT\u2019s potential expansion into CSU marks a critical step in addressing the unmet needs of more than <strong>300,000 people in the U.S.<\/strong> who live with the burden of inadequately controlled CSU. If approved, this therapy could redefine care standards for the condition.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-chmp-recommends-tagrisso-for-unresectable-egfr-mutated-lung-cancer\"><span class=\"ez-toc-section\" id=\"CHMP_Recommends_TAGRISSO_for_Unresectable_EGFR-Mutated_Lung_Cancer\"><\/span>CHMP Recommends TAGRISSO for Unresectable EGFR-Mutated Lung Cancer<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>AstraZeneca\u2019s <strong>TAGRISSO (osimertinib)<\/strong> has received a positive recommendation from the <strong>Committee for Medicinal Products for Human Use (CHMP)<\/strong> of the European Medicines Agency (EMA) for the treatment of adults with unresectable, locally <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-nsclc-market\" class=\"ek-link\">advanced <strong>EGFR-mutated <\/strong><\/a><strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-nsclc-market\" class=\"ek-link\">non<\/a><\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-nsclc-market\" class=\"ek-link\"><strong>-small cell lung cancer (NSCLC)<\/strong> <\/a>following platinum-based chemoradiation therapy (CRT). The endorsement is backed by groundbreaking findings from the <strong>LAURA Phase III trial<\/strong>, which showed that TAGRISSO extended median progression-free survival (PFS) to <strong>39.1 months<\/strong>\u2014a significant improvement compared to 5.6 months with placebo. These results reflect an <strong>84% reduction in disease progression or death<\/strong>.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Dr. <\/em><strong><em>Manuel Cobo<\/em><\/strong><em>, an investigator in the trial, emphasized the importance of the findings, stating, \u201cThe LAURA results build on the established efficacy of osimertinib and support the approval of the first targeted therapy for patients with unresectable, EGFR-mutated lung cancer.\u201d Similarly, <\/em><strong><em>Susan Galbraith<\/em><\/strong><em>, AstraZeneca\u2019s EVP for Oncology R&amp;D, remarked, \u201cToday\u2019s news reinforces TAGRISSO as the backbone therapy in EGFR-mutated non-small cell lung cancer&#8230; representing a pivotal step in transforming care for patients.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>TAGRISSO\u2019s safety profile in the LAURA trial aligns with its established tolerability, with no new safety concerns reported. This EU recommendation follows TAGRISSO\u2019s recent approval for similar indications in the U.S. and highlights its expanding global footprint, with regulatory reviews underway in China, Japan, and other countries.<\/p>\n\n\n\n<p>With more than 450,000 lung cancer diagnoses annually in Europe and approximately <strong>10-15% of NSCLC patients<\/strong> harboring EGFR mutations, TAGRISSO addresses a critical unmet need in a significant patient population. Already approved in over 100 countries for a range of EGFR-mutated NSCLC stages, including early-stage and metastatic settings, TAGRISSO continues to solidify its role as a leading therapy in lung cancer care.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-approves-danziten-for-chronic-myeloid-leukemia\"><span class=\"ez-toc-section\" id=\"FDA_Approves_DANZITEN_for_Chronic_Myeloid_Leukemia\"><\/span>FDA Approves DANZITEN for Chronic Myeloid Leukemia<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Azurity Pharmaceuticals has announced the <strong>FDA approval of DANZITEN\u2122<\/strong>, a groundbreaking formulation of nilotinib indicated for <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-myeloid-leukemia-market\" class=\"ek-link\">adults with newly diagnosed <\/a><strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-myeloid-leukemia-market\" class=\"ek-link\">Phi<\/a><\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-myeloid-leukemia-market\" class=\"ek-link\"><strong>ladelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)<\/strong><\/a> in chronic phase (CP) and for those with CP or acute phase (AP) resistant or intolerant to prior imatinib therapy. Unlike its predecessor, <strong>TASIGNA\u00ae, DANZITEN eliminates mealtime restrictions<\/strong>, offering a more patient-friendly treatment option without compromising efficacy.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Highlighting the advancement, Azurity CEO Richard Blackburn stated, \u201cDANZITEN offers a new nilotinib treatment option with the equivalent efficacy to Tasigna but without the fasting requirements, liberating CML patients from mealtime restrictions.\u201d This improvement addresses the fasting-related variability in <\/em><strong><em>Tasigna\u2019s bioavailability<\/em><\/strong><em>, which, when improperly taken with food, poses a risk of cardiotoxicity by prolonging the QT interval on ECG.<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>DANZITEN leverages a <strong>re-engineered formulation<\/strong> of nilotinib, ensuring consistent pharmacokinetics regardless of fasting state or meal type. With a lower dose, it achieves equivalent efficacy to Tasigna, delivering the <strong>deep molecular responses<\/strong> critical for treatment-free remission in some patients. By removing the fasting requirements, DANZITEN may enhance <strong>patient adherence<\/strong>, a crucial factor in achieving optimal outcomes.<\/p>\n\n\n\n<p>Set to launch in the coming weeks, DANZITEN will be available via <strong>Biologics by McKesson<\/strong>. Azurity also introduced the <strong>DANZITENCONNECT\u2122 program<\/strong>, offering support such as prior authorization assistance, co-pay reductions, and free initial treatment, easing accessibility for eligible patients.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-syndax-gains-fda-approval-for-revuforj-in-acute-leukemia\"><span class=\"ez-toc-section\" id=\"Syndax_Gains_FDA_Approval_for_REVUFORJ_in_Acute_Leukemia\"><\/span>Syndax Gains FDA Approval for REVUFORJ in Acute Leukemia<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <strong>FDA has approved Revuforj\u00ae (revumenib)<\/strong>, the first menin inhibitor, for <a href=\"https:\/\/www.delveinsight.com\/report-store\/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-epidemiology-forecast\" class=\"ek-link\">treating <strong>relapsed or refractory (R\/R)<\/strong><\/a><strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-epidemiology-forecast\" class=\"ek-link\"> acute leu<\/a><\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-epidemiology-forecast\" class=\"ek-link\"><strong>kemia<\/strong><\/a> with KMT2A translocations in patients aged one year and older. The approval, granted under the FDA&#8217;s <strong>Real Time Oncology Review (RTOR)<\/strong> program, marks a breakthrough for a condition with limited options and poor prognosis.\u00a0<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><strong><em>Michael A. Metzger, CEO of Syndax,<\/em><\/strong><em> highlighted the milestone, stating, &#8220;This approval reflects the dedication of our team and the patients and clinicians who participated in our trials. We are prepared to launch Revuforj this month and advance its development across the treatment continuum for KMT2A-rearranged acute leukemias.&#8221;<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Revuforj&#8217;s approval is based on the <strong>Phase I\/II AUGMENT-101 trial<\/strong>, which showed a <strong>21% complete remission rate<\/strong> (CR+CRh) in 104 patients, with a median remission duration of 6.4 months. Nearly a quarter of patients proceeded to stem cell transplantation, offering hope in a disease where conventional therapies often result in relapse and poor survival rates.&nbsp;<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Dr. Ghayas C. Issa of MD Anderson Cancer Center emphasized the therapy\u2019s significance: &#8220;This approval is a major breakthrough for patients with R\/R acute leukemia with KMT2A translocation, a genetic alteration associated with a poor prognosis. Revuforj\u2019s robust efficacy represents a substantial improvement over previously available therapies.&#8221;<\/em>The drug will be available in <strong>110 mg and 160 mg tablets<\/strong> starting in November through specialty distributors. A <strong>25 mg tablet<\/strong>, catering to patients under 40 kg, is expected by early 2025, with an oral solution available in the interim. Syndax is also launching <strong>SyndAccess\u2122<\/strong>, a support program offering financial assistance and personalized resources to ensure patient access.<\/p>\n<\/blockquote>\n","protected":false},"excerpt":{"rendered":"<p>FDA Approves AADC Deficiency Gene Therapy by PTC Therapeutics PTC Therapeutics, Inc. has secured FDA accelerated approval for KEBILIDI (eladocagene exuparvovec-tneq), marking a historic milestone as the first-ever gene therapy directly administered to the brain in the United States. This innovative therapy addresses aromatic L-amino acid decarboxylase (AADC) deficiency, a rare and life-threatening genetic disorder.&nbsp; [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":30363,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[18982,19119,204,704,349,420,6733,639,5789],"industry":[17225],"therapeutic_areas":[17237,17228,17234],"class_list":["post-30352","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-chronic-myeloid-leukemia","tag-chronic-spontaneous-urticaria","tag-delveinsight","tag-fda","tag-latest-pharma-news","tag-news","tag-non-small-cell-lung-cancer","tag-pharma-news","tag-recent-pharma-news","industry-pharmaceutical","therapeutic_areas-dermatology","therapeutic_areas-oncology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Regeneron, AstraZeneca, Syndax<\/title>\n<meta name=\"description\" content=\"PTC Therapeutics\u2019 AADC Gene Therapy, Sanofi and Regeneron\u2019s DUPIXENT, AstraZeneca\u2019s TAGRISSO, Syndax\u2019s REVUFORJ Approved\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-astrazeneca-syndax\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Regeneron, AstraZeneca, Syndax\" \/>\n<meta property=\"og:description\" content=\"PTC Therapeutics\u2019 AADC Gene Therapy, Sanofi and Regeneron\u2019s DUPIXENT, AstraZeneca\u2019s TAGRISSO, Syndax\u2019s REVUFORJ Approved\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-astrazeneca-syndax\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-19T08:14:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-19T08:15:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/19134410\/pharma-news-for-regeneron-astrazeneca-syndax.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Regeneron, AstraZeneca, Syndax","description":"PTC Therapeutics\u2019 AADC Gene Therapy, Sanofi and Regeneron\u2019s DUPIXENT, AstraZeneca\u2019s TAGRISSO, Syndax\u2019s REVUFORJ Approved","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-astrazeneca-syndax","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Regeneron, AstraZeneca, Syndax","og_description":"PTC Therapeutics\u2019 AADC Gene Therapy, Sanofi and Regeneron\u2019s DUPIXENT, AstraZeneca\u2019s TAGRISSO, Syndax\u2019s REVUFORJ Approved","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-astrazeneca-syndax","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-11-19T08:14:58+00:00","article_modified_time":"2024-11-19T08:15:00+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/19134410\/pharma-news-for-regeneron-astrazeneca-syndax.png","type":"image\/png"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-astrazeneca-syndax","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-astrazeneca-syndax","name":"Pharma News | Regeneron, AstraZeneca, Syndax","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-astrazeneca-syndax#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-astrazeneca-syndax#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/19134410\/pharma-news-for-regeneron-astrazeneca-syndax.png","datePublished":"2024-11-19T08:14:58+00:00","dateModified":"2024-11-19T08:15:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"PTC Therapeutics\u2019 AADC Gene Therapy, Sanofi and Regeneron\u2019s DUPIXENT, AstraZeneca\u2019s TAGRISSO, Syndax\u2019s REVUFORJ Approved","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-astrazeneca-syndax"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-astrazeneca-syndax#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/19134410\/pharma-news-for-regeneron-astrazeneca-syndax.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/19134410\/pharma-news-for-regeneron-astrazeneca-syndax.png","width":772,"height":482,"caption":"pharma-news-for-regeneron-astrazeneca-syndax"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/19134410\/pharma-news-for-regeneron-astrazeneca-syndax-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Chronic Myeloid Leukemia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Chronic Spontaneous Urticaria<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Non-small cell lung cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Chronic Myeloid Leukemia<\/span>","<span class=\"advgb-post-tax-term\">Chronic Spontaneous Urticaria<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">Non-small cell lung cancer<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Nov 19, 2024","modified":"Updated on Nov 19, 2024"},"absolute_dates_time":{"created":"Posted on Nov 19, 2024 1:44 pm","modified":"Updated on Nov 19, 2024 1:45 pm"},"featured_img_caption":"pharma-news-for-regeneron-astrazeneca-syndax  \n","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30352","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=30352"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30352\/revisions"}],"predecessor-version":[{"id":30364,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30352\/revisions\/30364"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/30363"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=30352"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=30352"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=30352"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=30352"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=30352"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}